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Type I and III interferons disrupt lung epithelial
repair during recovery from viral infection
Jack Major1, Stefania Crotta1, Miriam Llorian2, Teresa M. McCabe1*, Hans Henrik Gad3,
Simon L. Priestnall4,5, Rune Hartmann3, Andreas Wack1†
Excessive cytokine signaling frequently exacerbates lung tissue damage during respiratory viral
infection. Type I (IFN-a and IFN-b) and III (IFN-l) interferons are host-produced antiviral cytokines.
Prolonged IFN-a and IFN-b responses can lead to harmful proinflammatory effects, whereas
IFN-l mainly signals in epithelia, thereby inducing localized antiviral immunity. In this work, we show
that IFN signaling interferes with lung repair during influenza recovery in mice, with IFN-l driving
these effects most potently. IFN-induced protein p53 directly reduces epithelial proliferation and
differentiation, which increases disease severity and susceptibility to bacterial superinfections.
Thus, excessive or prolonged IFN production aggravates viral infection by impairing lung epithelial
regeneration. Timing and duration are therefore critical parameters of endogenous IFN action and
should be considered carefully for IFN therapeutic strategies against viral infections such as
influenza and coronavirus disease 2019 (COVID-19).
D
uring infection with respiratory viruses,
disease severity is linked to lung epithe-
lial destruction, owing to both cytopathic
viral effects and immune-mediated dam-
age. Epithelial loss contributes to acute
respiratory distress syndrome, pneumonia, and
increased susceptibility to bacterial superinfec-
tions. Thus, the restoration of damaged epithe-
lial tissues is paramount to maintain lung
function and barrier protection.
Interferons (IFNs) are key to the antiviral
host defense. IFN-a and IFN-b (IFN-a/b) and
IFN-l are induced upon viral recognition, and
they trigger transcription of IFN-stimulated
genes with antiviral functions in infected and
bystander cells. Because of widespread expres-
sion of the type I IFN receptor (IFNAR) in im-
mune cells, IFN-a/b responses can result in
immunopathology during viral infections, in-
cluding influenza virus and severe acute res-
piratory syndrome–coronavirus 1 (SARS-CoV-1)
(1–4). The IFN-l receptor (IFNLR) is mainly
expressed at epithelial barriers, and IFN-l
responses are therefore often characterized
by their ability to confer localized antiviral
protection at the site of infection without
driving damaging proinflammatory responses
like those associated with IFN-a/b. In addition
to antiviral and proinflammatory activity, IFNs
exert antiproliferative and proapoptotic func-
tions (5). Despite a growing understanding of
immunopathology in respiratory viral infec-
tion, it is unknown how IFN responses affect
lung epithelial repair.
Influenza virus infection in C57BL/6 (B6)
wild-type (WT) mice resulted in weight loss
accompanied by substantial immune cell in-
filtration and lung damage (fig. S1, A to D).
Recovery from infection coincided with the
onset of epithelial regeneration (fig. S1, B to
D). To further investigate the dynamics of lung
repair after influenza virus infection, epithelial
cell proliferation was analyzed by flow cytom-
etry using the proliferation marker Ki67 (see
gating strategy in fig. S2). During steady-state
conditions, type II alveolar epithelial (AT2)
cells (EpCam+MHCII+CD49f lo) (6–8) showed
a low rate of turnover (Fig. 1A). However, after
influenza virus–induced lung damage, AT2
cells underwent rapid proliferation starting
at days 5 to 7 after infection, which correlated
withmouse recovery and weight gain (Fig. 1A
and fig. S1B).
To compare the dynamics of epithelial re-
covery with IFN production, we analyzed IFN
subtypes (IFN-a, IFN-b, and IFN-l) in bron-
choalveolar lavage fluid (BALF) throughout
infection. IFNs were produced rapidly, peaking
2 days after infection (Fig. 1B). The magnitude
of IFN-l production was significantly greater
than that of IFN-a/b, both in duration and in
length of peak production. Notably, only IFN-l
was detected 7 to 8 days after infection, co-
inciding with the onset of epithelial recov-
ery (Fig. 1, A and B). Thus, after influenza
virus infection, signaling triggered by IFNs—
particularly by IFN-l—overlaps with the onset
of lung repair.
To compare the effects of equipotent amounts
of IFN-a, IFN-b, and IFN-l on lung repair,mice
were treated during recovery from influenza
virus infection (7 to 10 days after infection;
figs. S3A and S4). To study the effects of IFN
treatment specifically on epithelial cells, we
generated irradiation bonemarrow (BM) chi-
meras in which WT recipients were given
Ifnar1−/− BM cells (Ifnar1−/− → WT BM chi-
meric), thereby restricting IFNAR expression
to the stromal compartment.
In chimeric mice, both IFN-a and IFN-b
treatments significantly reduced the prolifer-
ation of AT2 cells on day 11 after influenza
virus infection (Fig. 1C). Similarly, IFN-l treat-
ment reduced AT2 cell proliferation in WT
mice (Fig. 1D). Reductions in proliferation
were independent of changes in viral burden
(fig. S3, B and C). The IFN-l–mediated reduc-
tion in AT2 cell proliferation did not require
IFN-l signaling in neutrophils (9–11), as neu-
trophil depletion in WT mice using an anti-
Ly6G monoclonal antibody had no effect (fig.
S3, D and E). A caveat to bear in mind when
using inbred mouse strains for influenza virus
infection is their lack of a functional Mx1 pro-
tein, a crucial IFN-inducible influenza virus
restriction factor in both mice and humans
(12). We therefore infected mice expressing
functional Mx1 alleles (B6-Mx1) with the in-
fluenza virus strain hvPR8-DNS1 for a more–
clinically relevant influenza model. IFN-l
treatment significantly reduced epithelial pro-
liferation in the presence of functional Mx1 as
well (Fig. 1E).
We next used Ifnar1−/− and Ifnlr1−/− mice
to determine the role of endogenous IFNs
during lung repair. AT2 cells were analyzed
on day 8 after influenza virus infection, the
time when IFN signaling and epithelial cell
proliferation overlapped (Fig. 1, A and B). Both
Ifnar1−/− and Ifnlr1−/−mice had improved AT2
cell proliferation compared with WT controls
(Fig. 1, F and G). This was dependent on IFN
signaling specifically through the epithelium,
because receptor deficiency in the stromal
compartment alone was sufficient to increase
lung epithelial cell proliferation (Fig. 1H). Im-
proved proliferation was independent of major
changes in viral burden (fig. S5A). Viral control
in individual IFN receptor–knockout mice was
likely unaffected owing to redundancy between
type I and III IFN antiviral responses in epi-
thelial cells (13, 14). Despite type I and III IFN
redundancy in viral control (fig. S5A), the
lack of redundancy in antiproliferative IFN
responses—with both Ifnar1−/− and Ifnlr1−/−
mice displaying enhanced epithelial prolif-
eration (Fig. 1, F to H)—led us to further in-
terrogate the phenotype. IFNAR signaling
has been previously shown to be important
for the production of IFN-l during influenza
virus infection (15, 16). Consistent with these
findings, we observed a significant reduction
in IFN-l (and in IFN-a/b) production in Ifnar1−/−
mice compared with WT; yet, we saw little
change in IFN-a/b levels in Ifnlr1−/− mice
(fig. S5B). Thus, the improved epithelial pro-
liferation in Ifnar1−/− mice may result from
reduced IFN-l. IFN production defects in
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Ifnar1−/− mice are linked to reduced steady-
state priming in the absence of tonic IFNAR
activation in immune cells (17). To circum-
vent this, we administered an anti-IFNAR
monoclonal antibody (MAR1-5A3) only from
the onset of influenza virus infection. Anti-
IFNAR treatment maintained steady-state
priming required for IFN-l production (fig.
S5C), despite blocking IFN-a/b signaling
through IFNAR (fig. S5D). Notably, anti-
IFNAR treatment from day 0 or day 3 after
infection had no effect on lung epithelial cell
proliferation (fig. S5E). Thus, in murine in-
fluenza virus infection, endogenous IFN-l
responses are most effective in disrupting
epithelial regeneration during influenza recov-
ery through direct effects on epithelial cells.
To understand mechanistically how IFNs
exert the observed antiproliferative effects,
we set up primary murine airway epithelial
cell (AEC) cultures. AECs undergo rapid pro-
liferation and differentiation upon exposure
to an air-liquid interface (ALI), which recapit-
ulates lung repair processes observed in vivo
(18, 19). IFNs used for in vitro assays were
titrated on AEC cultures to compare IFN sub-
types at equivalent biological potencies (fig. S6).
All three IFN subtypes significantly impaired
the growth of AEC cultures, with IFN-b and
IFN-l having the most significant effects (Fig. 2,
A to E, and fig. S7A). Similar effects were
observed when primary human AEC cultures
were treated with equivalent doses of IFN sub-
types (Fig. 2C). Growth inhibitory effects were
dependent on the presence of the respective
IFN receptor (fig. S7B). IFN-b or IFN-l treat-
ment increased the frequency of apoptotic
or necrotic cells (defined as annexin V+ and
TO-PRO-3+) (fig. S7, C and D); however,
the growth inhibitory effects of IFNs were
only observed in actively dividing cultures
(fig. S7, E to G). Thus, the increase in ap-
optosis observed may occur as a result of
failed progression through the cell cycle af-
ter IFN treatment, as has been seen previ-
ously (20).
We next examined the effects of IFNs on AEC
differentiation. After acute damage, populations
of basal cells and Scgb1a1+ secretory cells give
rise to secretory and multiciliated cell sub-
types (21). To study the effects of IFNs on AEC
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Fig. 1. Type I and III IFNs reduce epithelial cell proliferation during
lung repair. (A and B) Mice were infected intranasally with 104 TCID50
X31 (H3N2) influenza virus in 30 ml. (A) Proliferating (Ki67+) AT2 cells
(EpCam+MHCII+CD49flo) were measured by flow cytometry (n = 5 mice).
(B) Type I and III IFN levels were detected in BALF (n = 4) on indicated
days after infection. (C and D) X31-infected mice were administered
IFNs every 24 hours (on days 7 to 10 after infection). Proliferating (Ki67+)
AT2 cells (EpCam+MHCII+CD49flo) were measured by flow cytometry
on day 11 after infection. (C) Lethally irradiated WT mice were injected
with Ifnar1−/− BM cells. After reconstitution, influenza virus–infected
chimeric mice were treated with phosphate-buffered saline (PBS) control
(n = 8), IFN-a (n = 9), or IFN-b (n = 9). Naïve controls were uninfected,
untreated BM chimeric mice (n = 2). (D) Infected WT mice were treated with
IFN-l (n = 4) or PBS control (n = 4). Naïve controls were uninfected,
untreated WT mice (n = 5). IAV, influenza A virus. (E) B6-Mx1 mice were
infected with 2.5 × 103 TCID50 hvPR8-DNS1 (H1N1) and treated with IFN-l
(n = 4) or PBS control (n = 4). IFN treatment and lung analysis were
performed as for (C) and (D). (F to H) Lungs from X31-infected WT mice
(n = 4 to 7), Ifnar1−/− mice (n = 4) (F), Ifnlr1−/− mice (n = 7) (G), and BM
chimeric mice (n = 4 to 5) (H) were harvested; and proliferating (Ki67+)
AT2 cells were measured by flow cytometry on day 8 after infection.
All data are representative of at least two independent experiments. Data
are shown as means ± SEM, and statistical significance was assessed by
one-way analysis of variance (ANOVA) with Dunnett’s posttest [(C), (D),
and (H)] or unpaired two-tailed Student’s t test [(E) to (G)]. P > 0.05;
*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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Fig. 2. IFN signaling blocks AEC growth and differentiation. (A) Murine AECs
were seeded at a low density (500 cells per transwell) or high density (104 cells
per transwell) in the presence of equivalent doses of IFN-a, IFN-b, IFN-l, or
media control, and then grown for 12 days (n = 3 transwells for all conditions).
Confluence was determined by measuring transepithelial electrical resistance
(TEER) (>1000 ohm = confluent cultures). (B, D, and E) Proliferating murine AEC
cultures (2 days before exposure to an ALI) were treated for 5 days with IFNs
(2 days before ALI to day 3 after ALI), and effects on growth were determined by
cell number (n = 9) (B) and incorporation of the thymidine analog EdU to
measure proliferation (n = 9) [(D) and (E)]. DAPI, 4′,6-diamidino-2-phenylindole;
EdU, 5-ethynyl-2′-deoxyuridine. (C) Primary human AEC cultures were treated
with IFNs for 5 days and cells were counted (n = 4 to 6). (F and G) Murine AECs
were grown to confluence, then exposed to an ALI for 2 days. IFNs were then
administrated for 6 days during ALI exposure (n = 6 for all conditions).
Differentiation was determined by mRNA expression of the indicated genes (F)
and the level of acetylated a-tubulin staining in cultures (G). (H and I) WT and
Ifnlr1−/− mice were infected with influenza virus, and lungs were analyzed by
immunofluorescence (DAPI or acetylated a-tubulin) on day 10 after infection
(n = 4 mice) (H), and flow cytometry (EpCam+CD49fhiCD24+) on day 14 after
infection (n = 3) (I). All data are representative of at least three independent
experiments. Data are shown as means ± SEM, and statistical significance
was assessed by one-way [(B), (C), (E), and (G)] or two-way [(F) and (I)] ANOVA
with Dunnett’s posttest. Scale bar represents 100 mm (H). ns, not significant;
P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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Fig. 3. Type I and III IFNs activate antiproliferative and cell death path-
ways in AECs via induction of p53. (A) Schematic diagram for IFN
treatment of murine AECs for RNA-sequencing analysis. (B) PCA plot of
RNA-sequencing data from AECs after IFN treatment and from untreated
controls. (C) Heatmap for significant differences in canonical pathways for
nine pairwise comparisons between indicated IFN treatment and the
respective mock, at each time point (fold change >1.5, one-way ANOVA with
Benjamini-Hochberg correction, P < 0.05). Gene expression was compared
using ingenuity pathway comparison analysis. MHC, major histocompatibility
complex. (D) Predicted upstream transcriptional regulators of differentially
expressed genes (ingenuity pathway analysis). (E to G) WT and p53−/− murine
AECs were treated with IFN subtypes for 5 days and measured for growth
by cell number (E), CFSE (carboxyfluorescein diacetate succinimidyl ester)
dilution (F), and mRNA expression of indicated genes (G) (n = 3 transwells for
all conditions). (H and I) Ifnar1−/− → WT BM chimeric mice (n = 4 to 5 mice)
(H) and a-Ly6G treated mice (n = 4) (I) infected with influenza virus (X31),
and treated with IFN every 24 hours consecutively for 4 days (days 7 to 10
after infection), before EpCam+MHCII+CD49flo AT2 cells were analyzed for
p53 mean fluorescence intensity (MFI) on day 11 after infection by flow
cytometry. All data are representative of at least two independent
experiments [(E) to (I)]. Data are shown as means ± SEM, and statistical
significance was assessed by two-way [(E) to (G)] or one-way (H) ANOVA with
Dunnett’s posttest or by unpaired two-tailed Student’s t test (I). ns, not
significant; P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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differentiation, we initiated IFN treatment
late during the course of AEC growth, during
air exposure when AEC differentiation is in-
duced (fig. S8A). IFN-b and IFN-l treatment
significantly reduced the expression of genes
pertaining tomulticiliated (Mcidas and Ccno)
and secretory (Muc5AC and Scb1a1) cell differ-
entiation (Fig. 2F). Expression of the basal cell
marker Krt5 remained unchanged or was in-
creased by IFN-l treatment, which suggests
maintenance of stemness (fig. S8B). We also
found reduced numbers of multiciliated cells
in AEC cultures (acetylated a-tubulin+) after
IFN-l treatment, but we did not observe this
with IFN-a or IFN-b treatment (Fig. 2G and
fig. S8C). In vivo, Ifnlr1−/− mice displayed in-
creased multiciliated cells in repairing con-
ducting airways on day 10 after influenza virus
infection (Fig. 2H). Using flow cytometry, we
quantified this increase in the frequency of
differentiated AECs (EpCamhiCD49fhiCD24+)
composed of multiciliated, goblet, and club
cells (Fig. 2I and fig. S2) (22). Thus, IFN-l
signaling reduces the capacity for basal cell
differentiation during recovery from influ-
enza virus infection.
To understand how IFNs mediate antipro-
liferative effects,weperformedRNAsequencing
on IFN-treated AEC cultures (Fig. 3A). Principal
components analysis (PCA) clustered 4-hour
IFN-treated samples together regardless of
subtype (Fig. 3B), which confirmed equal sub-
type dosage on the basis of previous titrations
(fig. S9A). Five days of IFN-b or IFN-l treat-
ment clustered AECs together separately from
untreated controls on both PC1 and PC2 (Fig.
3B). Gene ontology analysis confirmed that
genes contributing to this variance are in-
volved in IFN signaling and epithelial cell
development (supplementary text and fig.
S9B). Ingenuity pathway analysis revealed
induction of pathways regulating cell cycle
and cell death after prolonged IFN treatment,
most significantly induced by IFN-l across all
time points (Fig. 3C). Predicted upstream tran-
scriptional regulators identified typical regu-
lators of IFN function—including STAT (signal
transducer and activator of transcription) and
IRF (IFN regulatory factor) proteins—in addi-
tion to cell cycle regulators (Fig. 3D). We iden-
tified the tumor suppressor protein p53 as a
top candidate regulating IFN-inducible anti-
proliferative effects. p53 has previously been
shown to directly regulate IFN-a/b antitumor
responses (23). Gene set enrichment analysis
(GSEA) identified IFN-mediated induction
of the p53 pathway (fig. S9C), and we iden-
tified induction of p53-regulated down-
stream targets in expression data (fig. S9D).
To confirm the role of p53, we utilized Tp53−/−
AEC cultures. IFN-mediated reduction in
AEC growth, differentiation, and induction
of antiproliferative downstream p53 target
genes Gadd45g and Dusp5 (24, 25) was p53-
dependent, with no changes observed in
Tp53−/− AECs (Fig. 3, E to G, and fig. S9E).
Wenext examinedwhether IFNs regulate p53
activity in epithelial cells during lung repair
in vivo. To study IFN effects specifically in
the lung epithelium, we once again generated
Ifnar1−/−→WT BM chimeric mice for IFN-a
or IFN-b treatment, and we depleted neu-
trophils inWTmice with anti-Ly6G for IFN-l
treatment (fig. S3A). IFN-b and IFN-l, but not
IFN-a, significantly up-regulated p53 expres-
sion in repairing lung epithelial cells (Fig. 3,
H and I). Thus, IFN-b and IFN-lmediate anti-
proliferative effects in AECs via the induction
of p53.
Our data support a key role for IFN sig-
naling, particularly IFN-l, in the reduction of
epithelial proliferation and differentiation
during lung repair.We therefore testedwheth-
er IFNs alter the state or barrier function of
lung epithelia. RNA sequencing of sorted
lung epithelial cells (EpCam+CD31−CD45−)
from influenza virus–infectedWT or Ifnlr1−/−
mice confirmed an up-regulation of pathways
pertaining to proliferation and multicilio-
genesis in Ifnlr1−/− mice (Fig. 4A). Improved
repair correlated with reduced lung damage,
with a reduction in both the total number of
cells and the number of red blood cells in the
BALF of Ifnlr1−/− mice at day 8 after infec-
tion (Fig. 4, B and C, and fig. S10A). Addi-
tionally, Ifnlr1−/− mice had fewer immune
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Fig. 4. Ifnlr1−/− mice have improved lung repair, reduced damage, and
improved epithelial barrier function. WT and Ifnlr1−/− mice were infected
with 104 TCID50 X31 influenza virus (X31). (A) GSEA plots of RNA-sequencing
datasets from WT or Ifnlr1−/− bulk lung epithelial cells (EpCam+) on day 8
after infection. FDR, false discovery rate; NES, normalized enrichment score;
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number in BALF on day 8 after infection (n = 4 mice for both WT and Ifnlr1−/−).
(D) Histopathological analysis of hematoxylin and eosin (H&E) lung sections
on day 9 after infection (n = 4 for both WT and Ifnlr1−/−). (E) Lethally
irradiated WT and Ifnlr1−/− mice were injected with WT BM cells. After
reconstitution, chimeric mice were challenged with 2 × 105 colony-forming
units TIGR4 in 30 ml on day 8 (d8) after influenza virus infection (n = 8 WT; n = 9
Ifnlr1−/−). All data are representative of at least two independent experiments
[(B) to (E)]. Data are shown as means ± SEM, and statistical significance
was assessed by unpaired two-tailed Student’s t test (B), Mann-Whitney U test
(D), or log-rank (Mantel-Cox) test (E). *P ≤ 0.05; **P ≤ 0.01.
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cells infiltrating lung tissue (Fig. 4D). In
humans, influenza virus–induced epithelial
damage increases susceptibility to infec-
tion by opportunistic bacterial pathogens,
including Streptococcus pneumoniae (26).
To measure the effects of IFN-l on lung
barrier function, we challenged influenza
virus–infected mice with S. pneumoniae. Both
full-IFNLR-knockout mice and mice lacking
IFNLR in the stromal compartment (WT→
Ifnlr1−/−) had improved survival after bac-
terial superinfection (Fig. 4E and fig. S10B).
Thus, IFN-l signaling reduces the capacity
for epithelial repair, which results in pro-
longed lung damage, compromised barrier
function, and increased susceptibility to bac-
terial superinfection.
In this work, we describe a mechanism by
which type I and III IFN signaling aggravates
lung pathology during respiratory viral infec-
tion. Although all three IFN subtypes reduced
lung proliferation after treatment during in-
fluenza recovery, only endogenous IFN-l com-
promised repair. This is likely because of
increased IFN-l production during infection
combined with greater induction of antipro-
liferative pathways. A recent study has shown
that IFN-l produced by dendritic cells inhib-
its lung epithelial repair after viral recognition
(27). Influenza virus–infected macaques have
been found to have an elevated IFN signature
late during infection in bronchial tissue (28).
Additionally, COVID-19 patients have displayed
strong induction of IFN and p53 signaling in
collected BALF samples (29). Analysis of lung
tissue and BALF from respiratory virus–infected
patients experiencing severe disease will pro-
vide insight into the mechanisms regulating
disease pathogenesis. IFN-l treatment early
during influenza virus infection is protective
in mice, offering antiviral protection without
the proinflammatory responses associated
with IFN-a/b (30, 31). By studying specific
effects in the respiratory epithelium, we iden-
tified a mechanism by which IFN exacerbates
respiratory virus disease, independent of im-
munomodulation. Our data indicate the need
for effective regulation of host IFN responses
and the importance of timing and duration
when considering IFNs as therapeutic strat-
egies to treat respiratory virus infections. Op-
timal protection could be achieved by strong
induction of IFN-stimulated genes early during
infection to curb viral replication followed
by timely down-regulation of IFN responses,
thereby enabling efficient lung epithelial
repair.
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Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
Andreas Wack
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, this issue p. 706, p. 712, p. 718; see also p. 626Science
respiratory infections.
timing, and duration of IFN exposure are critical parameters underlying the success or failure of therapeutics for viral
production, systemic production of IFNs may be beneficial. The results of this trio of studies suggest that the location, 
fueled responses. This suggests that in contrast to local−α and tumor necrosis factor-−proinflammatory interleukin-6
 blood immune cells from severe and critical COVID-19 patients have diminished type I IFN and enhanced
 observed that peripheral et al.inhibiting epithelial proliferation and differentiation. Complicating this picture, Hadjadj 
) hampers lung repair by inducing p53 andλ found that IFN signaling (especially IFN-et al.influenza infection, Major 
lung epithelium, which increases susceptibility to lethal bacterial superinfections. Similarly, using a mouse model of 
 secreted by dendritic cells in the lungs of mice exposed to synthetic viral RNA causes damage to theλFurthermore, IFN-
 report that COVID-19 patient morbidity correlates with the high expression of type I and III IFNs in the lung.et al.Broggi 
2019 (COVID-19) and other such viral respiratory diseases (see the Perspective by Grajales-Reyes and Colonna). 
 has been proposed as a therapeutic in coronavirus diseaseλdamaging proinflammatory responses. Accordingly, IFN-
responses are primarily restricted to mucosal surfaces and are thought to confer antiviral protection without driving 
)λ) are widely expressed and can result in immunopathology during viral infections. By contrast, type III IFN (IFN-βIFN-
 andαthe transcription of IFN-stimulated genes (ISGs), which engage in various antiviral functions. Type I IFNs (IFN-
Interferons (IFNs) are central to antiviral immunity. Viral recognition elicits IFN production, which in turn triggers
Interferons interfere with lung repair
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